Quick Answer
VERTEX PHARMACEUTICALS INC / MA reported Cash and Equivalents of $5.08 billion for fiscal year 2025.
VERTEX PHARMACEUTICALS INC / MA Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $5.08B | +11.3% |
| 2024 | $4.57B | -55.9% |
| 2023 | $10.37B | -1.3% |
| 2022 | $10.50B | +54.6% |
| 2021 | $6.79B | +13.5% |
| 2020 | $5.99B | +92.6% |
| 2019 | $3.11B | +17.3% |
| 2018 | $2.65B | +59.1% |
| 2017 | $1.67B | +40.7% |
| 2016 | $1.18B | +65.6% |
| 2015 | $714.77M | +14.3% |
| 2014 | $625.26M | +9.8% |
| 2013 | $569.30M | +16.3% |
| 2012 | $489.41M | +3.0% |
| 2011 | $475.32M | +95.4% |
| 2010 | $243.20M | -45.6% |
| 2009 | $446.66M | +14.8% |
| 2008 | $389.12M | +9.4% |
| 2007 | $355.66M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $4.94B | -5.7% | -0.7% |
| June 30, 2025 | $4.97B | +8.6% | +6.4% |
| March 31, 2025 | $4.67B | -49.0% | +2.3% |
| December 31, 2024 | $4.57B | -55.9% | -12.8% |
| September 30, 2024 | $5.24B | -52.8% | +14.4% |
| June 30, 2024 | $4.58B | -54.9% | -50.0% |
| March 31, 2024 | $9.16B | -1.4% | -11.7% |
| December 31, 2023 | $10.37B | -1.3% | -6.7% |
- VERTEX PHARMACEUTICALS INC / MA showed an increase of +11.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2007–2025 period, VERTEX PHARMACEUTICALS INC / MA’s cash and equivalents has grown by 1329.7% (from $355.66 million to $5.08 billion).
- The most recent figure is from VERTEX PHARMACEUTICALS INC / MA’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 13, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: